ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2025
Hypoxic Conditioned Medium Secretome from Mesenchymal Stem Cell Alleviates Sepsis by Targeting IL-6 and IL-4.
Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing MSCs plasticity: mechanisms and determinants of bidirectional immune regulation in stem-cell-based immunotherapy.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a state of immune response imbalance in an attempt to eliminate infection. Currently, the hypoxic conditioned medium (HPO-CM) secretome from mesenchymal stem cells (MSCs) has been considered as a therapeutic approach with their immunomodulatory capabilities. Objective: The aim of this article was to study the effect of HPO-CM secretome on the levels of IL-6 and IL-4 in the rat model of sepsis. Methods: Forty-eight male Rattus norvegicus rats aged 10-12 weeks were divided into four groups: sham (no sepsis induction and treatment), control (sepsis induction without treatment), T1 (sepsis induction and treated with 150 µL of HPO-CM secretome), and T2 (sepsis induction and treated with 300 µL of HPO-CM secretome). Sepsis was induced with procedures based on previous studies. Forty-eight hours after sepsis induction, we sacrificed the rats and collected the blood from the rat orbitals to examine the serum IL-6 and IL-4 levels. Results: A significant decrease in IL-6 levels was found in rats given 150 µL and 300 µL of HPO-CM secretome. Meanwhile, a significant increase in IL-4 levels was found in rats given 300 µL of HPO-CM secretome. Conclusion: HPO-CM secretome can alleviate immune dysregulation in sepsis by reducing serum IL-6 levels and increasing serum IL-4 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.